文献速递基础与转化研究临床试验与 GCP

阿尔茨海默病淀粉样蛋白清除的临床病理评估

Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease.
PubMed 文献 · JAMA · 2026-01-01

本病例报告描述一名携带p.R47H TREM2变异的轻度认知障碍男性,接受aducanumab治疗30次(累积剂量280 mg/kg)共4.5年,死后尸检显示淀粉样蛋白清除区域与较少的tau病理和较慢的纵向皮质萎缩相关,而高淀粉样蛋白负荷区域tau病理与未治疗对照相似。

要点

  • 淀粉样蛋白广泛清除区域与较少的下游tau病理和较慢的皮质萎缩相关。
  • 淀粉样蛋白清除优先发生于脑回顶部,高负荷区域多位于脑沟深处。
  • 实现下游神经病理获益可能需要广泛的淀粉样蛋白清除。

核心结论

  • 淀粉样蛋白靶向治疗后广泛清除区域与较少的下游神经病理改变相关。
  • 淀粉样蛋白清除似乎优先发生于脑回顶部。

研究设计与样本

  • 单中心学术记忆中心的临床病理病例报告。
  • 纳入一名携带p.R47H TREM2变异的50余岁轻度认知障碍男性,接受aducanumab治疗。

主要发现

  • 患者接受30次aducanumab,累积剂量280 mg/kg,历时4.5年,末次给药4年后死亡。
  • 尸检显示淀粉样蛋白病理水平不一,低淀粉样蛋白区域与高淀粉样蛋白区域并存。
  • 与对照相比,治疗后低淀粉样蛋白区域优先位于脑回顶部,伴有较少的tau病理。
  • 低淀粉样蛋白区域与较慢的纵向皮质萎缩相关(β = -0.50 [95% CI, -0.62 to -0.37];t = -7.96,P < .001)。
  • 高淀粉样蛋白负荷区域优先位于脑沟深处,tau病理水平与未治疗对照相似。

临床怎么用

  • 提示淀粉样蛋白清除可能延缓下游tau病理和神经退行性变。
  • 脑回顶部和脑沟深处的清除差异可能影响治疗效果评估。

局限性

  • 为单例病例报告,结论不能推广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The long-term efficacy of amyloid-targeting therapies hinges on their ability to slow downstream neuropathologic change, but little is known about the influence of amyloid clearance on tau pathology and neurodegeneration. OBJECTIVE: To determine the postmortem and in vivo association between amyloid levels and downstream neuropathology after treatment with aducanumab in a patient with patchy areas showing minimal residual amyloid levels. DESIGN, SETTING, AND PARTICIPANTS: This clinicopathologic case report from a single academic memory center includes a male carrier of the p.R47H TREM2 variant, which is associated with a higher risk of Alzheimer disease, who was in his 50s, had mild cognitive impairment, and received aducanumab while participating in a randomized clinical trial. Fourteen untreated controls, who were matched by age or presence of the TREM2 variant, also are included. EXPOSURES: The male carrier of the p.R47H TREM2 variant had received 30 doses of aducanumab (cumulative dose of 280 mg/kg) over 4.5 years. MAIN OUTCOMES AND MEASURES: Neuropathologic evaluation at autopsy, positron emission tomography to measure standardized uptake value ratio as a measure of amyloid and tau levels, and magnetic resonance imaging to determine longitudinal change in cortical thickness. RESULTS: Four years after receiving the final dose of aducanumab, the patient died. An autopsy showed variable levels of amyloid pathology, including brain regions with very low levels of amyloid juxtaposed with brain regions that had typically high levels of amyloid in the deep cortical layers and only low levels of amyloid in the superficial cortical layers. Compared with the brain regions of the untreated controls, the brain regions of the patient after treatment with aducanumab showed low levels of amyloid that were preferentially found in the gyral crests, were associated with less tau pathology at autopsy, and were associated with slower longitudinal atrophy on in vivo magnetic resonance imaging (β = -0.50 [95% CI, -0.62 to -0.37]; t = -7.96 and P < .001). In contrast, the patient's brain regions with high amyloid burden were preferentially found in the sulcal depths and had similar levels of tau pathology as seen at autopsy in the untreated controls. CONCLUSIONS AND RELEVANCE: In this case report, areas of extensive amyloid clearance after amyloid-targeting therapy were associated with less downstream neuropathologic change. In addition, amyloid clearance appears to preferentially occur in the gyral crests. Future studies should evaluate the differential mechanisms involved in amyloid clearance from superficial and deep cortical layers and in gyri and sulci because extensive amyloid clearance may be necessary to achieve downstream neuropathologic benefit after removal of amyloid.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Brown CA, Robinson JL, Das SR, et al. Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease. JAMA. 2026. PMID: 42437499. doi:10.1001/jama.2026.13058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。